Showing results (91-100 of 196) with videos related to
Sort By:
Pageof 20
American Journal of Hematology|September 27, 2008
Trisomy 8 in an allogeneic stem cell transplant recipient representative of a donor-derived constitutional abnormalityNoelle V Frey, Christopher E Leid, Peter C Nowell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2022
Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy StudiesYimei Li, Wei-Ting Hwang, Shannon L Maude, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 28, 2014
Acute cholecystitis is a common complication after allogeneic stem cell transplantation and is associated with the use of total parenteral nutritionStephen J Bagley, Alison R Sehgal, Saar Gill, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 7, 2018
Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated DonorsLisa M Crisalli, Joanne T Hinkle, Christopher C Walling, et al.Blood|January 7, 2017
Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxisRyan H Moy, Austin P Huffman, Lee P Richman, et al.Journal for Immunotherapy of Cancer|December 28, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphomaSattva S Neelapu, Sherry Adkins, Stephen M Ansell, et al.Journal of Hematotherapy & Stem Cell Research|June 14, 2003
Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantationJohn Gerecitano, Clarissa Mathias, Rosemarie Mick, et al.American Journal of Hematology|March 26, 2016
Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomasClinton Yam, Daniel J Landsburg, Kevin T Nead, et al.Transplantation and Cellular Therapy|January 23, 2025
Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell TherapyLuke Maillie, Sunita D Nasta, Jakub Svoboda, et al.Clinical Lymphoma|July 3, 2003
Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibodyDonald E Tsai, Ivan Maillard, Stephen J Schuster, et al.Pageof 20